Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study.

Milena ShrashimirovaIvan TyanevWiesław Jerzy CubałaAdam WichniakClaudia Vodickova-BorzovaAlessandro RuggieriAnnalisa BonelliPaola LiponeAlessandro ComandiniAgnese Cattaneo

Published in: Neuropsychiatric disease and treatment (2023)

To our knowledge, this is the first observational, long-term study in patients suffering from MDD, conducted with TzOAD. The improvement observed in clinical response, overall functioning, depressive symptoms, and QoL along the 24 weeks (+4) maintenance period and the very good retention rate, suggest that TzOAD may represent an effective and well tolerated treatment option for patients suffering from MDD.

Keyphrases

end stage renal disease
depressive symptoms
ejection fraction
newly diagnosed
major depressive disorder
chronic kidney disease
prognostic factors
healthcare
sleep quality